Type II Diabetes
Below is a sample of existing clinical evidence:“WJ-MSC (Wharton’s Jelly MSC) transplantation significantly decreased the levels of glucose and glycated hemoglobin, improved C-peptide levels and beta cell function, and reduced markers of systemic inflammation and T lymphocyte counts… Treatment with WJ-MSCs can improve metabolic control and beta cell function in patients with T2DM.”
– “A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus,” Liu et al, Stem Cell Research & Therapy, 2014